Bivalent Vaccine Effectiveness Against Anal Human Papillomavirus Positivity Among Female Sexually Transmitted Infection Clinic Visitors in the Netherlands

Petra J Woestenberg*, Audrey J King, Birgit H B Van Benthem, Suzan Leussink, Marianne A B Van der Sande, Christian J P A Hoebe, Johannes A Bogaards, Medical Microbiological Laboratories and the Public Health Services

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review


Human papillomavirus (HPV) vaccines are indicated for anal cancer prevention, but evidence for vaccine effectiveness (VE) against anal HPV infections among women is limited. We estimated the VE (≥1 dose) against anal HPV positivity of the bivalent vaccine, whose target types HPV-16/18 are associated with approximately 90% of HPV-related anal cancers. Among 548 female STI clinic visitors 16-24 years old who provided an anal swab sample as part of a repeated cross-sectional survey, VE against HPV-16/18 was 89.9% (95% confidence interval, 63.0%-97.2%). Type-specific VE correlated well with VE against cervicovaginal HPV (Spearman ρ = 0.76), suggesting comparable effectiveness of HPV-16/18 vaccination against genital and anal infections.

Original languageEnglish
Pages (from-to)1280-1285
Number of pages6
JournalJournal of Infectious Diseases
Issue number8
Publication statusPublished - 15 Apr 2020


  • Human papillomavirus (HPV)
  • human papillomavirus vaccine
  • vaccine effectiveness
  • public health
  • anal cancer
  • RISK

Cite this